Kalaris Therapeutics
KLRS
81 hedge funds and large institutions have $28.8M invested in Kalaris Therapeutics in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 35 closing their positions.
5,580% more call options, than puts
Call options by funds: $284K | Put options by funds: $5K
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
0.43% less ownership
Funds ownership: 2.05% → 1.62% (-0.43%)
10% less funds holding
Funds holding: 90 → 81 (-9)
26% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 35
75% less capital invested
Capital invested by funds: $115M → $28.8M (-$86.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.42M |
| 2 |
Morgan Stanley
New York
|
+$808K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$762K |
| 4 |
Renaissance Technologies
New York
|
+$734K |
| 5 |
D.E. Shaw & Co
New York
|
+$433K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$9.9M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
-$9.05M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.84M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$4.35M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$1.79M |
KLRS Hedge Fund Activity: Q4 2023 in Review
81 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q4 2023, worth a combined $28.8M — down 75% from $115M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of KLRS and 26 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 22 added.
The largest buyer was Millennium Management, adding an estimated $5.42M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $9.9M sold.
- 81 institutional investors held Kalaris Therapeutics (KLRS) as of Q4 2023, down from 90 in Q3 2023.
- Funds reported $28.8M of Kalaris Therapeutics stock for Q4 2023, down 75% quarter-over-quarter.
- 26 funds opened new Kalaris Therapeutics positions in Q4 2023 and 35 closed out, a net change of -9 holders.
- The largest Kalaris Therapeutics buyer in Q4 2023 was Millennium Management, an estimated $5.42M added.
- The largest Kalaris Therapeutics seller in Q4 2023 was Alkeon Capital Management, an estimated $9.9M sold.
Based on aggregated 13F filings for Q4 2023.